Genetics of common disease and diagnostics
Through its CLIA-registered testing facility deCODE currently offers DNA-based tests for gauging genetic risk of Myocardial Infarction (MI), Type 2 Diabetes (T2D), Atrial Fibrillation (AF), Glaucoma (Glaucoma) and Prostate Cancer (ProCa):
- for gauging risk of Type 2 Diabetes
deCODE T2™ is aimed at helping
physicians assess the genetic risk of type 2 diabetes in their patients,
and to enable lifestyle and therapeutic strategies that may reduce the
risk of developing diabetes in the future.
Download Order Forms
Read more >>
- for gauging risk of Atrial Fibrillation
deCODE AF™ offers a novel means of identifying those who may
benefit from outpatient cardiac monitoring after leaving the hospital.
Download Order Forms
Read more >>
- for gauging risk of MI
deCODE MI™ detects previously unrecognized genetic risk of MI that appears to be in addition to welll known risk factors such as elevated cholesterol and hypertension. The test may be positive even in patients of families without history of heart attacks.
Download Order Forms
Read more >>
- for gauging risk of Glaucoma
deCODE Glaucoma™ is a reference laboratory DNA test for assessing an inherited risk factor for exfoliation glaucoma. The deCODE Glaucoma™ test detects versions of SNPs (single nucleotide polymorphism) – single letter variations in the sequence of the genome – in a specific gene that deCODE has linked to increased risk of one of the more common types of glaucoma, exfoliation type glaucoma.
Download Order Forms
Read more >>
- for gauging risk of Prostate Cancer
deCODE ProCa™ is a reference laboratory DNA test for assessing an inherited risk factor for Prostate Cancer.
Download Order Forms
Read more >>
About deCODE genetics
deCODE is a global leader in gene discovery - our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer.
Read more >>